The final score was calculated using (i) the scaled sum of B cells and FDC CD21+ CD23- densities (log10), and (ii) the TLS scaled relative area, which were the three most prognostically relevant and robust TLS features in this NSCLC cohort. This evidence concerns the gene FCER2 and non-small cell lung carcinoma.